Intended Use: MOTS-c is designed for Research Purposes only.

Storage: Store the vial in a cool, dry place away from direct sunlight. Once reconstituted, keep refrigerated at 2-8°C.

Solubility: Reconstitute with bacteriostatic water for best results.

Shelf Life: The lyophilized form has a shelf life of 24 months when properly stored. Once reconstituted, refrigerate and use within 4-6 weeks.

Handling: Ensure sterile techniques are used to maintain the product’s integrity during research.

Observations from clinical literature.

Dose‑dependent weight loss of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 obesity trials.
Improvements in liver‑related biomarkers in NAFLD/NASH populations.
Meta‑analysis confirms consistent weight‑loss efficacy across multiple randomized controlled trials.
Adverse effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation (most common during dose escalation).
Gradual titration helps mitigate GI tolerability issues.

Survodutide is a dual agonist that activates both GLP‑1 and glucagon receptors. The GLP‑1 component enhances satiety and improves glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation. This dual mechanism is hypothesized to provide additive or synergistic effects on body weight and liver fat beyond GLP‑1 agonism alone. In phase 2 trials, survodutide demonstrated substantial weight loss alongside improvements in liver enzyme markers.

BAC Water Sold Separately
Syringes Not Included
Peptides sold in powdered form

Survodutide

Guaranteed Fast Delivery!

Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks.